000141178 001__ 141178
000141178 005__ 20240229105121.0
000141178 0247_ $$2doi$$a10.1038/s41416-018-0264-x
000141178 0247_ $$2pmid$$apmid:30287914
000141178 0247_ $$2ISSN$$a0007-0920
000141178 0247_ $$2ISSN$$a1532-1827
000141178 0247_ $$2altmetric$$aaltmetric:49312506
000141178 037__ $$aDKFZ-2018-01705
000141178 041__ $$aeng
000141178 082__ $$a610
000141178 1001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b0$$eFirst author$$udkfz
000141178 245__ $$aThe colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention.
000141178 260__ $$aEdinburgh$$bNature Publ. Group$$c2018
000141178 3367_ $$2DRIVER$$aarticle
000141178 3367_ $$2DataCite$$aOutput Types/Journal article
000141178 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659531739_29252$$xReview Article
000141178 3367_ $$2BibTeX$$aARTICLE
000141178 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141178 3367_ $$00$$2EndNote$$aJournal Article
000141178 520__ $$aColorectal cancer (CRC) is both one of the most common and one of the most preventable cancers globally, with powerful but strongly missed potential for primary, secondary and tertiary prevention. CRC incidence has traditionally been the highest in affluent Western countries, but it is now increasing rapidly with economic development in many other parts of the world. CRC shares several main risk factors, such as smoking, excessive alcohol consumption, physical inactivity and being overweight, with other common diseases; therefore, primary prevention efforts to reduce these risk factors are expected to have multiple beneficial effects that extend beyond CRC prevention, and should have high public health impact. A sizeable reduction in the incidence and mortality of CRC can also be achieved by offering effective screening tests, such as faecal immunochemical tests, flexible sigmoidoscopy and colonoscopy, in organised screening programmes which have been implemented in an increasing number of countries. Countries with early and high uptake rates of effective screening have exhibited major declines in CRC incidence and mortality, in contrast to most other countries. Finally, increasing evidence shows that the prognosis and quality of life of CRC patients can be substantially improved by tertiary prevention measures, such as the administration of low-dose aspirin and the promotion of physical activity.
000141178 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141178 588__ $$aDataset connected to CrossRef, PubMed,
000141178 7001_ $$0P:(DE-He78)b3928caa1d0865f09ffc5cf5e7683da6$$aChen, Chen$$b1$$eLast author$$udkfz
000141178 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-018-0264-x$$gVol. 119, no. 7, p. 785 - 792$$n7$$p785 - 792$$tBritish journal of cancer$$v119$$x1532-1827$$y2018
000141178 909CO $$ooai:inrepo02.dkfz.de:141178$$pVDB
000141178 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141178 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b3928caa1d0865f09ffc5cf5e7683da6$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141178 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141178 9141_ $$y2018
000141178 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141178 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141178 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141178 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141178 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2017
000141178 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141178 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141178 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141178 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141178 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141178 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141178 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141178 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141178 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141178 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2017
000141178 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000141178 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000141178 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000141178 980__ $$ajournal
000141178 980__ $$aVDB
000141178 980__ $$aI:(DE-He78)C070-20160331
000141178 980__ $$aI:(DE-He78)G110-20160331
000141178 980__ $$aI:(DE-He78)L101-20160331
000141178 980__ $$aUNRESTRICTED